Compare Natera Inc. Common Stock (NTRA) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Sunrun Inc — how do they compare? Natera Inc. Common Stock trades at $392.22 (market cap $57.03B), while Sunrun Inc trades at $7.29 (market cap $1.88B). The key difference: Natera Inc. Common Stock is far larger — about 30.3× Sunrun Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Sunrun Inc for 16 Days on average.
| NTRA | RUN | |
|---|---|---|
Market Cap | $57.03B | $1.88B |
Volume | 1,131,157 | 7,327,146 |
Sector | Health | Energy |
52-Week High | $425.64 | $21.41 |
52-Week Low | $179.42 | $7.30 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $56.18B | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Sunrun (RUN) trades at $7.79, up 2.64% on the day, but remains in a bearish technical trend with strong selling pressure in moving averages. The stock shows attractive valuation metrics with P/E of 5.3 and P/B of 0.54, while consistently beating earnings expectations in recent quarters. Recent developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions.
Despite positive analyst sentiment (62% buy ratings) and a $15.40 consensus price target representing 98% upside, RUN faces significant headwinds including negative operating cash flow, high debt levels (70.76% debt-to-asset ratio), and solar industry pressure from elevated borrowing costs. The stock trades near its analyst low target of $7.00, suggesting limited downside but requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
